Table 1 Baseline characteristics of the study patients
Median age, years (range)55 (22–75)
Female, no. (%)18 (75)
Disease status:
Median disease duration, years (range)12 (0.9–50)
Erosive disease, no. (%)24 (100)
Nodular disease, no. (%)9 (38)
Median IgM-RF, kU/litre (IQR)75 (46–159)
Median ACPA, kU/litre (IQR)240 (95–1031)
Median DAS28, (IQR)6.5 (1.1)
Median ESR, mm/h (IQR)37 (19–55)
Median CRP, mg/dl (IQR)24 (10–76)
Median no. of previous DMARDs, (IQR)4 (2–5)
Median no. of previous biological agents, (IQR)2 (1–3)
Median methotrexate dosage, mg/week (IQR)15 (10–25)
Corticosteroids, no. (%)16 (67)
Median prednisone dosage, mg/day (IQR)5 (0–10)
  • ACPA, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; IQR, interquartile range; RF, rheumatoid factor.